Accelerating Nanomedicine from Concept to Preclinical Proof of Value
Nanoparticle-enabled therapeutics—including lipid nanoparticles (LNPs), polymeric nanocarriers, and inorganic nanosystems—are redefining drug delivery for mRNA therapeutics, siRNA, gene editing, biologics, and next-generation vaccines. To successfully advance these complex modalities toward the clinic, developers in pharmaceutical companies, biotech firms, and emerging RNA-therapy innovators require precise, reproducible, and regulatory-compliant evaluation across both cellular and in vivo models.
Our integrated Nanoparticle Cellular & In Vivo Evaluation Services deliver a comprehensive suite of preclinical capabilities that support each stage of nanoparticle R&D. From early formulation behavior, cellular uptake, and mechanistic assays, to in vivo biodistribution, PK/PD, and disease-model pharmacology, we provide end-to-end scientific insights that help you optimize delivery efficiency, validate therapeutic potential, and derisk development decisions. Whether your program involves LNP-mRNA vaccines, siRNA delivery systems, targeted polymeric nanoparticles, or novel nanomaterial-based therapeutics, Our services equip your team with high-quality, decision-ready data that turns scientific innovation into actionable development outcomes.
Modern nanomedicine platforms—such as LNPs, polymeric nanoparticles, liposomes, and inorganic nanosystems—offer powerful capabilities for targeted drug delivery and RNA therapeutics. However, these systems introduce unique development challenges that cannot be addressed through traditional small-molecule or biologic workflows. Rigorous cellular and in vivo evaluation is essential to reduce risk, optimize formulation performance, and meet regulatory expectations.
Complex Biological Behavior: Nanoparticles interact with cells, proteins, and tissues in ways that traditional drugs do not. Robust evaluation is required to understand how these interactions influence delivery, efficacy, and safety.
Delivery Efficiency as a Bottleneck: For mRNA, siRNA, and targeted therapies, delivery—not the payload—often determines success. In vitro and in vivo studies reveal whether a formulation can reach the right cells and release its cargo effectively.
Regulatory Expectations: Agencies increasingly require biodistribution, PK/PD, and mechanistic data for nanoparticle-based therapeutics. Early evaluation ensures a smooth regulatory path and reduces the risk of delays at IND submission.
Sensitivity to Formulation Changes: Small adjustments in size, charge, or composition can dramatically alter biological performance. Comprehensive testing helps identify formulation attributes that truly drive therapeutic success.
Cost and Time Efficiency: Early screening of nanoparticle candidates prevents costly late-stage failures. Data-driven decisions at the cellular and early in vivo stages streamline the entire development timeline.
Modality-Specific Requirements: RNA therapies and nanocarriers demand specialized assays to assess expression, knockdown, targeting, and immune activation. Proper evaluation ensures each modality performs as intended in biologically relevant systems.
Mechanistic insight and early-stage screening for nanoparticle performance.
Cellular Uptake & Trafficking
Nucleic Acid Delivery & Functional Readouts
Cytotoxicity, Biocompatibility & Mechanistic Safety
Cell-Nanoparticle Interface Characterization
Translational insights to validate delivery efficiency, safety, and therapeutic potential.
Biodistribution & Pharmacokinetics (PK)
Pharmacodynamics & Efficacy Models
Oncology Models
Immunology & Inflammation
Metabolic & Organ-Specific Models
RNA Therapeutics Models
Safety & Tolerability Studies
Dose Optimization & Translational Modeling
Critical quality attribute (CQA) profiling for data-driven formulation development.
Nanoparticle Structural & Morphological Analysis
Encapsulation & Release Behavior
Composition & Purity Assessment
Bioanalytical Support
A value-added service often overlooked by competitors.
Early Feasibility & Proof-of-Concept Design
IND-Enabling Preclinical Planning
Formulation Optimization Guidance
| Service Module | Included Capabilities | Typical Outputs |
| Cellular Evaluation (In Vitro) | Cellular uptake, cytotoxicity, mRNA/siRNA activity assays, trafficking analysis | IC50, uptake curves, confocal images, gene expression data |
| In Vivo Biodistribution & PK | Fluorescence/bioluminescence imaging, LC-MS/MS quantification, organ distribution | PK curves, half-life, AUC, organ-level accumulation |
| Efficacy & Pharmacodynamics (PD) | Tumor models, immunology models, RNA activity readouts | Tumor inhibition %, cytokine profiles, biomarker changes |
| Safety & Tolerability | Hematology, histopathology | Toxicity reports, safety margins, GLP-ready data |
| Analytical & Characterization | Particle size, PDI, zeta potential, encapsulation, release | Stability reports, TEM/cryo-TEM images, CQA profiling |
Different nanoparticle modalities require distinct analytical, cellular, and in vivo evaluation strategies. The matrix below outlines the major nanoparticle types we support and the corresponding testing services available for each platform, helping developers quickly identify the capabilities most relevant to their programs.
| Nanoparticle Type | Typical Applications | Available Evaluation Services |
| Lipid Nanoparticles (LNPs) | mRNA/siRNA/ASO, gene editing | Cellular uptake, mRNA expression, biodistribution, PK/PD, immunogenicity |
| Polymeric Nanoparticles (PLGA, PEG-PLGA, micelles) | Small molecules, peptides, proteins | Release profiling, tumor accumulation, stability, toxicity |
| Liposomes | Oncology, anti-inflammatory, vaccines | Encapsulation efficiency, particle stability, tumor targeting |
| Inorganic Nanoparticles (Au, Fe3O4, silica) | Imaging, targeted therapy | Biodistribution, clearance, organ toxicity |
| Protein-based Nanoparticles (exosome, albumin) | Biologics, nucleic acids | Cargo loading, uptake, in vivo tracing |
Scope definition, recommended assays, and technical consultation.
Physicochemical and stability testing.
Uptake, activity, safety.
Route-specific delivery behavior.
Disease models, PD markers, toxicity.
Structured reports with detailed datasets, visualized results, and transparent methodology to support scientific interpretation and project progression.
Cross-Disciplinary ExpertiseIntegrated knowledge across nanotechnology, drug delivery, pharmacology, and RNA therapeutics ensures scientifically robust study designs.
End-to-End EvaluationFrom formulation characterization to cellular assays and in vivo pharmacology, we provide a complete continuum of nanoparticle assessment.
Advanced Analytics & ImagingHigh-resolution bioanalytical, qPCR, LC-MS/MS, and cryo-TEM platforms deliver precise, publication-grade insights.
Validated Disease ModelsA broad panel of oncology, immunology, metabolic, and vaccine models accelerates therapeutic proof-of-concept.
Flexible Engagement ModelsChoose single-module assays or fully integrated programs tailored to your development stage.
High Reproducibility & Quality StandardsRigorous QC and standardized protocols guarantee data you can trust.
| Industry | Key Needs | How Our Platform Supports Them |
| Pharma | IND-ready datasets, robust PK/PD, formulation evaluation | Full preclinical package, disease models, regulatory-aligned reporting |
| Biotech | Fast iteration, prototype screening | Rapid in vitro screening + integrated in vivo validation |
| mRNA/Vaccine Developers | Immune response, LNP optimization | Immunogenicity panels, antigen expression, biodistribution |
| Gene Therapy | Delivery efficiency, off-target safety | RNA delivery assays, CRISPR activity, immunotoxicity |
| Academic/Institute | Mechanistic studies, advanced imaging | Cryo-TEM, mechanistic cell studies, flexible bespoke projects |
We support a wide range of nanoparticle platforms, including lipid nanoparticles (LNPs), polymeric nanoparticles (PLGA, PEG-PLGA, micelles), liposomes, protein-based nanoparticles (exosomes, albumin), inorganic particles (gold, iron oxide, silica), nanoemulsions, and nanocrystals.
Yes. We provide full in vitro and in vivo evaluation for mRNA, siRNA, ASO, CRISPR components, and other nucleic acid therapeutics, including transfection efficiency, gene expression analysis, biodistribution, and immune response profiling.
Typical assays include:
We conduct biodistribution and PK/PD studies, efficacy assessments in validated disease models (tumor, immune, metabolic), and safety evaluations including chemistry panels, hematology, and histopathology.
Yes. We offer multiple biodistribution modalities:
Advancing a nanoparticle-based therapeutic requires more than isolated assays—it demands a partner who understands how formulation science, cellular mechanisms, in vivo pharmacology, and regulatory strategy converge to shape successful drug development. Our Nanoparticle Cellular & In Vivo Evaluation platform is engineered to provide exactly that level of scientific depth and operational reliability. Whether you are evaluating a new LNP for mRNA delivery, optimizing a polymeric carrier for targeted oncology applications, or validating next-generation inorganic nanomaterials, we offer data-driven insights, validated models, and expert guidance to help you transition from early discovery to preclinical proof-of-concept with confidence. Connect with us today to discuss your nanoparticle program, request a proposal, or schedule a scientific consultation.
